Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

被引：0
|
作者：
Shijie Lu
Yake Lou
Yi Rong
Zirui Huang
Xiaodan Lin
Junying Chen
Kongjia Luo
机构：
[1] Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[2] The Second Affiliated Hospital of Chongqing Medical University,Department of Cardiology
来源：
Clinical Drug Investigation | 2023年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：643 / 652
页数：9
相关论文
共 50 条
  • [21] First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis
    Liang, Xueyan
    Meng, Mingyu
    Qin, Shiran
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [22] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [23] Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
    You, Maojin
    Huang, Yufan
    Cai, Zhongjie
    Wu, Qingfeng
    Zhu, Wei
    He, Ying
    Chen, Ruijia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Peng-Fei Zhang
    Xuan-Qiong Shi
    Qiu Li
    Cost Effectiveness and Resource Allocation, 21
  • [25] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Shi, Xuan-Qiong
    Li, Qiu
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [26] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [27] Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
    Qiu, Hai-Bo
    THORACIC CANCER, 2020, 11 (12) : 3419 - 3421
  • [28] Tislelizumab plus chemotherapy for esophageal squamous cell carcinoma
    Andres, Ulrike
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (11):
  • [29] Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma
    Zheng, Hanrui
    Li, Jiafeng
    Wen, Feng
    Su, Na
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Fang, Rui
    Wang, Suiqiong
    Liu, Yongqian
    Xu, Jun
    ADVANCES IN THERAPY, 2023, 40 (03) : 1019 - 1030
12345